J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?
Yahoo Finance · Sep 24, 2026 · Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
Contineum Therapeutics, Inc. (NASDAQ:CTNM) has received the result biotech investors never want to see: one of its partnered drugs missed the primary endpoint of a Phase 2 trial. JNJ-5120/PIPE-307, which Contineum developed and Johnson & Johnson (NYSE:JNJ) is advancing under a global license and development agreement, failed to demonstrate the required efficacy in the Phase […]
Not investment advice. Headline and summary only, not a full reprint.